Organogenesis Holdings Inc. (ORGO) shares rose 6.48 percent, up $0.145 to $2.385 on Tuesday, after the company announced positive results from a randomized controlled trial evaluating PuraPly AM in non-healing diabetic foot ulcers.
The stock is currently trading at $2.385, above its previous close of $2.24, after opening at $2.49 on the Nasdaq. Shares traded in a range of $2.37 to $2.63 during the session, with volume surging to 12.63 million shares, far above the average daily volume of 669,888.
Organogenesis' 52-week range is $2.21 to $7.077. The company said the 170-patient multi-center trial achieved its primary endpoint, showing statistically significant wound closure at 12 weeks versus standard of care alone, with a p-value below 0.0477. Management said the results support broader clinical evidence for PuraPly AM and may strengthen future reimbursement and coverage discussions in diabetic wound care.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.